Michael Sidler

Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland.

Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006.

ACREDIS qmc AG engages in the provision of project and quality management, marketing, procurement, logistics, and distribution services for the healthcare, hotel, and restaurant service providers focusing on consumer and durable goods. It also acquires participating interests in firms, as well as acquires, manages, and sells licenses, patents, and other intangible assets. The company was founded by Stephan Hägeli on February 22, 2006 and is headquartered in Zurich, Switzerland.

Part of The Boston Consulting Group, Inc., Boston Consulting Group Holding AG operates as a holding Swiss company. The company is based in Zurich, Switzerland. Founded in 1963.

BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland.

Redbiotec AG develops and produces multi protein assemblies. It specializes in producing virus-like particles, various types of protein complexes and single proteins and VLP-based vaccines against various infectious diseases. The firms products are used in complex drug target, structural studies, target validation, antibody generation, biopharmaceutical and VLP applications. The company was founded in 2006 by Christian Schaub and Corinne John and is headquartered in Schlieren, Switzerland.

Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland.

MedMira Holding AG operates as a holding company with interests in developing and manufacturing medical diagnostics and technologies. The firm provides medical progress to customers from all over the world while combining the quality with economical sustainability. The company was founded on December 22, 2008 and is headquartered in Zug, Switzerland.